System and Method for VLM-Guided Closed-Loop Plant-Based Opioid-Agonist Micro-Delivery for Productivity-Linked Reward Conditioning

Abstract

Disclosed is a system and method for closed-loop productivity-linked reward conditioning via a wearable transdermal micro-pump delivering plant-based opioid-agonist compounds (mitragynine, 7-hydroxymitragynine, and synthetic analogs thereof) under the real-time guidance of a vision-language model (VLM) that observes, classifies, and verifies the user's cognitive activity against user-specified productivity goals. The system comprises: (1) a wearable dermal micro-pump with transdermal mitragynine delivery validated through biocompatible polymer matrix diffusion; (2) a camera-based observation system feeding a VLM that classifies the user's activity type (reading, writing, coding, mathematical derivation, patent drafting, musical composition) and evaluates engagement depth via behavioral correlates (pupil dilation, fixation patterns, typing cadence, postural stability, micro-expression analysis); (3) a goal-matching engine that compares the classified activity against user-defined target domains (constitutional law, fusion energy research, novel invention, software engineering, scholarly writing); (4) a reward-delivery controller that triggers micro-doses (0.5–5.0 mg mitragynine equivalent) when the VLM confirms genuine engagement with the target activity for sustained periods (configurable: 8–25 minutes); (5) a titrated dose-reduction protocol that gradually lowers reward magnitude as the session progresses, preventing receptor downregulation and dependency; and (6) a session-debrief module that logs the work produced, reward delivered, and subjective experience to refine future dosing via Bayesian optimization. The system creates a Pavlovian association between deep intellectual work and euphoric neurochemical reward, leveraging the mu-opioid agonist properties of mitragynine (which exhibits a ceiling effect on respiratory depression unlike classical opioids) to condition sustained productive behavior without the addiction liability of synthetic opioids or the side-effect profile of stimulant-based cognitive enhancers.

Field of the Invention

This invention relates to closed-loop drug delivery systems, specifically to a wearable transdermal pump delivering micro-doses of plant-derived opioid-agonist compounds under the control of a vision-language model that verifies user engagement in goal-specified intellectual activities, creating a neurochemical reward conditioning loop for sustained productive cognition.

Background

Existing cognitive enhancement strategies fall into three categories, each with fundamental limitations:

• Stimulants (amphetamine, methylphenidate, modafinil, caffeine): Push the nervous system into arousal. Side effects include anxiety, sleep disruption, tolerance buildup, and diminished effect over time. They force focus but do not make the work feel rewarding.
• Nootropics (racetams, choline sources, adaptogens): Mild cognitive support with unclear efficacy. No reward conditioning effect. No closed-loop adaptation.
• Behavioral techniques (Pomodoro, flow-state training, gamification): Effective for some users but rely on willpower and external motivation. No neurochemical reinforcement of the focus state itself.

None of these approaches address the core problem: deep intellectual work is not neurochemically rewarding for most people. The brain's dopamine system evolved to reward food, social validation, and novelty — not constitutional law, plasma physics, or patent drafting. Social media platforms exploit this mismatch by delivering engineered dopamine hits for low-effort engagement (scrolling, liking), creating a competitive disadvantage for sustained deep work.

Mitragynine, the primary alkaloid of Mitragyna speciosa (kratom), is a partial mu-opioid receptor agonist that produces analgesia, mild euphoria, and anxiolysis at low doses (Kruegel et al., 2019). Critically, mitragynine exhibits a ceiling effect on respiratory depression, meaning that above a certain dose, additional compound does not further depress breathing — a safety profile fundamentally superior to classical opioids (Hassan et al., 2021). Transdermal delivery of mitragynine has been validated through biocompatible polymer matrix patches (Wungsintaweekul, 2026), demonstrating sustained systemic delivery with first-pass metabolism bypass.

Meanwhile, vision-language models (VLMs) have achieved sufficient capability to reliably classify human activities from video feeds, including reading vs. writing vs. coding vs. passive consumption, and to estimate engagement depth from behavioral correlates (OpenVLM, 2024). The convergence of these two technologies enables a novel system: a VLM that confirms you are actually studying constitutional law, paired with a pump that delivers a euphoric plant-based reward when you do.

Summary of the Invention

The disclosed system, designated NEUROPUMP, comprises the following integrated subsystems:

1. Transdermal Micro-Pump Assembly

A wearable dermal patch (30–60 mm diameter) containing a microporous polymer matrix loaded with mitragynine base (or 7-hydroxymitragynine, or synthetic analogs such as MG001) in a reservoir of 50–500 mg total capacity. Delivery is actuated by a piezoelectric micropump capable of dispensing 0.1–5.0 mg per pulse through a 5×5 mm dermal interface area. The pump supports continuous basal delivery (0.1–0.5 mg/hour), bolus reward pulses (0.5–5.0 mg), and programmable dose ramps. Biocompatible adhesive compatible with 7-day wear cycles. Bluetooth Low Energy interface for dosing commands from the companion application.

2. VLM Observation and Activity Classification Engine

A camera (wearable, desk-mounted, or integrated display) streams video to a VLM (e.g., GPT-4V-class, LLaVA-class, or specialized fine-tuned model) at 1–5 fps. The VLM performs:

• Activity classification: Reading text, writing (keyboard/handwriting), coding, mathematical derivation, CAD/design work, passive screen consumption, phone use, disengagement
• Domain classification: Subject matter identification via OCR of visible text, code syntax detection, diagram classification — matching against user goals (e.g., "constitutional law," "fusion plasma physics," "mechanical invention")
• Engagement scoring: Composite metric from gaze fixation duration, micro-saccade frequency, blink rate, postural micro-movements, and typing/annotation cadence. Output: 0–100 engagement score sampled at 10-second intervals
• Anti-spoofing: Detection of fake engagement patterns (holding a book open while scrolling phone, displaying text while watching video). Penalties for disengagement during an active reward window

3. Goal Configuration Interface

The user defines target activities through a mobile application, including:

• Goal domains: e.g., "Read Federalist Papers," "Draft patent application," "Study Tokamak confinement physics," "Write code in Rust"
• Session targets: Duration goals (e.g., 90-minute deep work blocks), frequency targets (e.g., 2 sessions/day)
• Reward profile: User-selectable reward character — "Gentle warmth" (low dose, gradual), "Breakthrough burst" (higher dose, faster onset), "Sustained flow" (continuous low basal)
• Safety bounds: Maximum daily mitragynine exposure (default: 15 mg/day), session frequency limits, mandatory off-days (minimum 2/week)

4. Reward Delivery Controller

The dosing algorithm operates as a closed-loop controller:

• Trigger condition: VLM engagement score ≥ 70/100 AND activity matches a goal domain for ≥ 8 minutes (configurable)
• Reward dose: 0.5–5.0 mg mitragynine equivalent, modulated by engagement score, time since last dose, and cumulative daily exposure
• Basal mode: Optional low-dose continuous delivery (0.1–0.3 mg/hour) during confirmed goal-matched engagement
• Titrated withdrawal: As session approaches its target end, reward doses are reduced by 25% per pulse, preventing abrupt neurochemical drop-off
• Session end protocol: 15-minute wind-down with no further dosing, allowing natural receptor recovery

5. Reinforcement Analytics Engine

Post-session, the system logs: total work time, reward delivered, engagement trajectory, artifacts produced (via screen capture word count / commit count / page count), and subjective quality rating (user input). A Bayesian optimizer (Gaussian process surrogate) updates the per-user reward model to maximize long-term productivity while minimizing dose escalation. The optimizer enforces a hard constraint on week-over-week dose increase (≤10%), preventing tolerance-driven spirals.

Detailed Description

Pharmacological Rationale

Mitragynine (C23H30N2O4, MW 398.5) is the predominant indole alkaloid of Mitragyna speciosa, comprising ~66% of total alkaloid content. At low doses (1–5 mg, transdermal), mitragynine acts as a partial mu-opioid receptor agonist with additional activity at delta and kappa receptors, producing mild euphoria, anxiolysis, and enhanced focus — without the pronounced sedation or respiratory depression of full agonists. The partial agonist profile and β-arrestin pathway bias (Váradi et al., 2016) provide an intrinsic safety ceiling that classical opioids lack.

Transdermal delivery bypasses hepatic first-pass metabolism, which destroys ~80% of oral mitragynine via CYP3A4. This reduces the required dose by approximately 5× compared to oral consumption, lowering total alkaloid exposure and GI side effects while maintaining therapeutic plasma levels.

VLM Activity Classification

The observation system uses a fine-tuned VLM trained on a labeled dataset of 50,000+ hours of work-session video, annotated with activity type, subject domain, and engagement quality scores. The model outputs a structured JSON classification at each frame:

{
  "activity": "reading",
  "domain": "constitutional_law",
  "source_text_detected": "Federalist No. 47 — The Particular Structure...",
  "engagement_score": 84,
  "confidence": 0.92,
  "behavioral_correlates": {
    "gaze_fixation_ms": 4200,
    "blink_rate_per_min": 8,
    "postural_stability": 0.78,
    "annotation_activity": true
  },
  "anti_spoofing": {
    "phone_detected": false,
    "secondary_screen_content": "unrelated_video",
    "spoof_probability": 0.03
  }
}

Dose-Response and Safety Architecture

The system implements a multi-layer safety architecture:

• Per-dose maximum: 5.0 mg mitragynine equivalent per reward pulse
• Daily maximum: 15 mg total (adjustable down, not up)
• Weekly maximum: 70 mg
• Mandatory off-days: Minimum 2 days/week with zero dosing
• Tolerance monitoring: If engagement-to-reward ratio degrades >20% week-over-week, system reduces dosing and notifies user
• Emergency stop: Hardware button on patch + software kill switch in app
• Receptor recovery protocol: After 6 consecutive use-days, mandatory 48-hour washout period

Use Cases

The Constitutional Scholar

Goal: Read and annotate Federalist Papers for 3 hours/day. The VLM confirms the user is reading primary source constitutional text (via OCR), annotating actively, and maintaining fixation. Micro-doses delivered at 12-minute intervals sustain a gentle euphoric association with the study of foundational law. Over 8 weeks, the user reports genuine anticipation and pleasure when opening the text — the work itself has become the reward.

The Fusion Researcher

Goal: Deep literature review on magnetic confinement plasma physics. The VLM classifies reading of arXiv papers with physics-domain LaTeX equations, sustained note-taking, and citation graph construction. Reward pulses coincide with moments of apparent insight (detected via increased annotation rate + engagement spike), conditioning the brain to find breakthrough moments more euphoric.

The Inventor

Goal: Draft 5 patent applications. The VLM detects CAD work, technical writing, and prior-art searching. Reward delivery is tied to completion milestones (claim sets drafted, figures finalized), creating a dopamine-like reward loop around the patent drafting process itself rather than the eventual outcome.

The Founder

Goal: Prepare investor pitch deck. The VLM confirms slide design, financial modeling, and narrative work. Reward conditioning targets the anxiety-producing parts of founder work — financial projections, competitive analysis — making the hardest tasks feel manageable.

Comparison to Existing Cognitive Enhancement

Approach	Mechanism	Reward Conditioning	Safety Profile
NEUROPUMP	Partial μ-agonist, transdermal	✅ Euphoric reward tied to verified work	Ceiling effect, titrated withdrawal, mandatory off-days
Adderall / Ritalin	Amphetamine, oral	❌ Forces arousal, no reward association	Addiction, sleep disruption, cardiovascular strain
Modafinil	Orexin/wakefulness, oral	❌ Wakefulness without euphoria	Generally safe but no conditioning effect
Caffeine + L-theanine	Adenosine antagonist, oral	❌ Mild alertness only	Safe, weak effect, tolerance builds
Gamification apps	Behavioral, digital	⚠️ Extrinsic (badges, streaks)	Safe but ineffective long-term

Ethical and Regulatory Considerations

This disclosure acknowledges significant ethical concerns:

• Dependency risk: Any opioid-agonist, even partial, carries dependency potential. The ceiling effect, mandatory off-days, and tolerance monitoring reduce but do not eliminate this risk.
• Surveillance: A camera observing work sessions raises privacy concerns. All processing should occur on-device (edge inference) with no video retention.
• Regulatory status: Kratom is unscheduled under US federal law but regulated or banned in 6 states. Mitragynine is a controlled substance in Thailand, Malaysia, and Australia. The NIH begins Phase I human trials of purified mitragynine (MG001) in September 2026.
• Equity: A system that makes deep work euphoric could create a productivity divide between those with access and those without.
• This is defensive prior art, not a medical device. The purpose of this disclosure is to ensure the concept enters the public domain and cannot be patented.

Claims (Defensive)

1. A wearable transdermal micro-pump system for delivering mitragynine, 7-hydroxymitragynine, or synthetic analogs thereof, controlled by a software application receiving input from a vision-language model that classifies user activity.
2. The system of claim 1, wherein the VLM compares classified activity against user-specified goal domains and triggers reward dosing only when the activity matches the goal.
3. The system of claim 1, wherein the VLM estimates engagement depth from behavioral correlates including gaze fixation, blink rate, typing cadence, and postural stability.
4. The system of claim 1, further comprising anti-spoofing detection to prevent reward delivery during simulated engagement.
5. The system of claim 1, further comprising a titrated withdrawal protocol that reduces reward magnitude as sessions progress.
6. The system of claim 1, further comprising a Bayesian optimization engine that personalizes dosing based on observed productivity outcomes.
7. The system of claim 1, wherein mandatory off-days and cumulative dose caps prevent receptor downregulation.
8. The system of claim 1, further comprising a session-debrief module logging work artifacts produced, reward delivered, and subjective experience.